Norfloxacin
- Generic Name
- Norfloxacin
- Drug Type
- Small Molecule
- Chemical Formula
- C16H18FN3O3
- CAS Number
- 70458-96-7
- Unique Ingredient Identifier
- N0F8P22L1P
- Background
A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.
- Indication
For the treatment of urinary tract infection
- Associated Conditions
- Cystitis, Gonococcal cervicitis, Infectious diarrhea, Pyelitis, Pyelonephritis, Spontaneous Bacterial Peritonitis (SBP), Traveler's Diarrhea, Urethritis gonococcal
Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting.
- First Posted Date
- 2009-12-25
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 253
- Registration Number
- NCT01039545
- Locations
- 🇨🇭
Institute for Infectious Diseases, University of Berne, Berne, Switzerland
Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 291
- Registration Number
- NCT01037959
- Locations
- 🇫🇷
Assisatnce publique Hoptitaux de Paris, Clichy, France
Evaluation of Safety & Efficacy of Synbiotic on the Incidence and Recurrence of Spontaneous Bacterial Peritonitis (SBP) in Cirrhotics
- Conditions
- Cirrhosis With Ascites
- Interventions
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2009-07-28
- Lead Sponsor
- Govind Ballabh Pant Hospital
- Target Recruit Count
- 110
- Registration Number
- NCT00947336
- Locations
- 🇮🇳
Department of Gastroenterology, G B Pant Hospital, New Delhi, Delhi, India
Role of Probiotics in the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Randomized Placebo Control Trial
- Conditions
- Spontaneous Bacterial PeritonitisLiver Cirrhosis
- Interventions
- Drug: Probiotics and Placebo
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2008-05-15
- Lead Sponsor
- All India Institute of Medical Sciences, New Delhi
- Target Recruit Count
- 250
- Registration Number
- NCT00678613
- Locations
- 🇮🇳
All India Institute of Medical Sciences, New Delhi, Delhi, India
A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 9
- Registration Number
- NCT00362752
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis
- Conditions
- Spontaneous Bacterial PeritonitisHepatorenal SyndromeCirrhosis
- First Posted Date
- 2006-08-03
- Last Posted Date
- 2006-08-03
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 70
- Registration Number
- NCT00359853
- Locations
- 🇪🇸
Hospital Clinic Barcelona, Barcelona, Catalonia, Spain
Vasoactive Peptides in Portal Pressure
- Conditions
- Portal Hypertension
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2007-07-26
- Lead Sponsor
- Bayside Health
- Registration Number
- NCT00163982
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.